Cited by 321Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Open access

Ferris, Robert L., Jaffee, Elizabeth M., Ferrone, Soldano·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.27.6360PMC PMC2954137

Open this paper in CoChat — free account

Abstract

PURPOSE: Tumor antigen (TA) -targeted monoclonal antibodies (mAb), rituximab, trastuzumab, and cetuximab, are clinically effective for some advanced malignancies, especially in conjunction with chemotherapy and/or radiotherapy. However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response. METHODS: We reviewed the evidence indicating that the effects of TA-targeted mAb-based immunotherapy are mediated not only by inhibition of signaling pathways, but also by cell-mediated cytotoxicity triggered by the infused TA-targeted mAb. We analyzed the immunologic variables that can influence the outcome of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro and in animal model systems. We also analyzed the correlation reported between these variables and the clinical response to mAb-based immunotherapy. RESULTS: Of the variables that influence ADCC mediated by TA-targeted mAb, only polymorphisms of Fcγ receptors (FcγR) expressed by patients' lymphocytes were correlated with clinical efficacy. However, this correlation is not absolute and is not observed in all malignancies. Thus other variables may be responsible for the antitumor effects seen in mAb-treated patients. We discuss the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy. CONCLUSION: Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.6360

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
IgG Fc Receptors
Ravetch, J. V., & Bolland, S. M. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,686
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,319
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,272
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112

Flagged first, then by citations

Show all 122 references

Research works printed but not linked: 9

Abes R, Blood
Reilly RT, 2001, Cancer Res, 61, 880
Sharafanski M, Head and Neck
Valentini AM, 2008, Curr Opin Mol Ther, 10, 124
Zhao WP, 2009, Oncol Rep, 21, 1405
Whiteside TL, 1996, Anticancer Res, 16, 2357
Ugurel S, 2002, Onkologie, 25, 129
Li D, 2002, Cancer Res, 62, 4023
10.1158/1078-0432.CCR-05-2750 · DOI

Sorted by citations

Items 101–200 of 321

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
Pous, A., Notario, L., Hierro, C., Layos, L., & Bugés, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411403 · Cited by 51
Cetuximab in the treatment of squamous cell carcinoma of the head and neck
Specenier, P. M., & Vermorken, J. B. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.20 · Cited by 47
Induction of Wnt-Inducible Signaling Protein-1 Correlates with Invasive Breast Cancer Oncogenesis and Reduced Type 1 Cell-Mediated Cytotoxic Immunity: A Retrospective Study
Klinke, D. J. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003409 · Cited by 47
Personalized Medicine in Oncology: Where Have we Come From and Where are we Going?
André, F., Ciccolini, J., Spano, J., Penault-Llorca, F. M., Mounier, N., Freyer, G., Blay, J., & Milano, G. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.79 · Cited by 45
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
Вячеславовна, А. Е., Popova, L. I., Zamyatnin, A. A., Werner, J. M., Mikhailovsky, N. V., & Bazhin, A. V. (2021) · Vaccines · doi:10.3390/vaccines9111363 · Cited by 45
Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell–Tumor Cell Interactions
Deguine, J., Bréart, B., Lemaı̂tre, F., & Bousso, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202065 · Cited by 44
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Wang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 45
Self-citation
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway
van Maldegem, A. M., Bovée, J. V. M. G., Peterse, E., Hogendoorn, P. C. W., & Gelderblom, H. A. J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.009 · Cited by 43
Polymer Microspheres and Their Application in Cancer Diagnosis and Treatment
Zhai, M., Wu, P., Liao, Y., Wu, L., & Zhao, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126556 · Cited by 41
The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right
Park, D. S., Robertson‐Tessi, M., Luddy, K. A., Maini, P. K., Bonsall, M. B., Gatenby, R. A., & Anderson, A. R. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3712 · Cited by 41
Natural killer cells in cancer immunotherapy
Wang, D., Dou, L., Sui, L., Xue, Y., & Xu, S. (2024) · MedComm · doi:10.1002/mco2.626 · Cited by 47
The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities
Freiser, M. E., Serafini, P., & Weed, D. T. (2013) · Immunologic Research · doi:10.1007/s12026-013-8462-3 · Cited by 41
Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro.
Morisaki, T., Umebayashi, M., Kiyota, A., Koya, N., Tanaka, H., Onishi, H., & Katano, M. (2012) · PubMed · Cited by 39
Clinical Development of the E75 Vaccine in Breast Cancer
Clifton, G. T., Gall, V., Peoples, G. E., & Mittendorf, E. A. (2016) · Breast Care · doi:10.1159/000446097 · Cited by 38
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects
Qin, H., Zhou, Z., Shi, R., Mai, Y., Xu, Y., Fu, P., Cheng, G., Zhang, Z., Chen, W., Chen, Y., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01701-6 · Cited by 43
Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
Klöß, S., Chambron, N., Gardlowski, T., Weil, S., Koch, J., Esser, R., von Strandmann, E. P., Morgan, M. A., Arseniev, L., Seitz, O., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00543 · Cited by 38
Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review
Hosseini, M., Seyedpour, S., Khodaei, B., Loghman, A. H., Seyedpour, N., Yazdi, M. H., & Rezaei, N. (2023) · Vaccines · doi:10.3390/vaccines11010146 · Cited by 38
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
Sondel, P. M., & Gillies, S. D. (2012) · Antibodies · doi:10.3390/antib1020149 · Cited by 38
Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma
Han, T. K., Abdel‐Motal, U. M., Chang, D.-K., Sui, J., Muvaffak, A., Campbell, J. J., Zhu, Q. K., Kupper, T. S., & Marasco, W. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044455 · Cited by 36
Immune Stimulating Antibody‐Photosensitizer Conjugates via Fc‐Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS‐Mutated Pancreatic Cancer Treatment
Kim, D., Lee, S., & Na, K. (2021) · Small · doi:10.1002/smll.202006650 · Cited by 37
Human Tumor–Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis
Singhal, S. K., Rao, A. S., Stadanlick, J. E., Bruns, K., Sullivan, N. T., Bermudez, A. F., Honig-Frand, A., Krouse, R., Arambepola, S., Guo, E., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2135 · Cited by 41
Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy
Bou-Dargham, M. J., Draughon, S. A., Cantrell, V., Khamis, Z. I., & Sang, Q. A. (2021) · Journal of Cancer · doi:10.7150/jca.64205 · Cited by 37
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
Mateo, J., Berlin, J. D., Bono, J. S. D., Cohen, R. B., Keedy, V. L., Mugundu, G. M., Zhang, L., Abbattista, A., Davis, C. B., Stampino, C. G., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2576-8 · Cited by 35
Antitumor Antibodies Can Drive Therapeutic T Cell Responses
Wittrup, K. D. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.07.001 · Cited by 35
A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
Chen, Y.-L., Cui, Y., Liu, X., Liu, G., Dong, X., Tang, L., Hung, Y., Wang, C., & Feng, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101420 · Cited by 35
PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer
McGale, J., Khurana, S., Huang, A., Roa, T., Yeh, R., Shirini, D., Doshi, P., Nakhla, A., Bebawy, M., Khalil, D., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154882 · Cited by 34
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Schoppy, D. W., & Sunwoo, J. B. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.07.009 · Cited by 34
An update on the role of daratumumab in the treatment of multiple myeloma
Costello, C. L. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716677523 · Cited by 34
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
Bonomo, P., Desideri, I., Loi, M., Mangoni, M., Sottili, M., Marrazzo, L., Talamonti, C., Greto, D., Pallotta, S., & Livi, L. (2018) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2018.01.005 · Cited by 34
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Ferris, R. L., Moskovitz, J. M., Kunning, S. R., Ruffin, A. T., Reeder, C., Ohr, J. P., Gooding, W. E., Kim, S., Karlovits, B. J., Vignali, D. A. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0426 · Cited by 34
Self-citation
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
Wirt, T., Roßkopf, S., Rösner, T., Eichholz, K. M., Kahrs, A. J., Lutz, S., Kretschmer, A., Valerius, T., Klausz, K., Otte, A., et al. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479978 · Cited by 36
Targeting of Antigens to B Lymphocytes via CD19 as a Means for Tumor Vaccine Development
Ma, Y., Xiang, D., Sun, J., Ding, C., Liu, M., Hu, X., Li, G., Kloecker, G. H., Zhang, H., & Yan, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203216 · Cited by 33
Alpha-enolase (ENO1), identified as an antigen to monoclonal antibody 12C7, promotes the self-renewal and malignant phenotype of lung cancer stem cells by AMPK/mTOR pathway
Shu, X., Cao, K.-Y., Liu, H., Yu, L., Sun, L., Yang, Z., Wu, C., & Ran, Y. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02160-9 · Cited by 33
Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer
Kersh, A. E., Ng, S., Chang, Y. M., Sasaki, M., Thomas, S. N., Kissick, H. T., Lesinski, G. B., Kudchadkar, R. R., Waller, E. K., & Pollack, B. P. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1028 · Cited by 33
Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations
Saga, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1626 · Cited by 32
High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
Liu, Y., Lü, Q., Liang, J.-W., Xia, Y., Zhang, W., Hu, B., Shang, F., Ji, Y.-R., Wang, J., Wang, Q., et al. (2015) · Medicine · doi:10.1097/md.0000000000000481 · Cited by 31
IgE‐based immunotherapy of cancer: challenges and chances
Singer, J., & Jensen‐Jarolim, E. (2013) · Allergy · doi:10.1111/all.12276 · Cited by 30
Cancer immunotherapy: are we there yet?
Li, Z., Chen, L., & Rubinstein, M. P. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-33 · Cited by 31
Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma
Augustin, J., Soussan, P., & Bass, A. J. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.001 · Cited by 33
Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma
Lim, C. M., Liou, A. K. F., Poon, M. L. M., Koh, L. P., Tan, L. K., Loh, K. S., Petersson, B. F., Ting, E. Y., Campana, D., Goh, B. C., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03158-9 · Cited by 29
p16, HPV, and Cetuximab: What Is the Evidence?
Bonner, J. A., Mesı́a, R., Giralt, J., Psyrri, A. K., Keilholz, U., Rosenthal, D. I., Beier, F., Schulten, J., & Vermorken, J. B. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0433 · Cited by 28
Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell–specific Stimulation and Therapeutic Monoclonal Antibodies
Hoeres, T., Pretscher, D., Holzmann, E., Smetak, M., Birkmann, J., Triebel, J., Bertsch, T., & Wilhelm, M. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000289 · Cited by 28
The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy
Hamilton, G., & Plangger, A. (2021) · Biologics · doi:10.2147/btt.s290305 · Cited by 28
Cannabinoid Receptor-1 suppresses M2 macrophage polarization in colorectal cancer by downregulating EGFR
Deng, Y., Zhao, C., Wu, L., Qu, Z., & Wang, X. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01064-8 · Cited by 27
Cancer immunotherapy: Progress and challenges in the clinical setting
Zarour, H. M., & Ferrone, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201190035 · Cited by 27
Self-citation
Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma
Ly, L. V., Sluijter, M., van der Burg, S. H., Jager, M. J., & van Hall, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200135 · Cited by 28
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Bertino, E. M., McMichael, E. L., Mo, X. M., Trikha, P., Davis, M. E., Paul, B. K., Grever, M. R., Carson, W. E., & Otterson, G. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0879 · Cited by 27
The CC′ loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation
Kundapura, S. V., & Ramagopal, U. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-54623-y · Cited by 25
Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies
Karmakar, S., Pal, P., & Lal, G. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306109 · Cited by 31
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
Gambardella, V., Fleitas, T., Tarazona, N., Cejalvo, J. M., Gimeno-Valiente, F., Martínez‐Ciarpaglini, C., Huerta, M., Roselló, S., Castillo, J., Roda, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz143 · Cited by 25
Redirecting natural killer cells to potentiate adoptive immunotherapy in solid tumors through stabilized Y-type bispecific aptamer
Zheng, Y., Zhang, C., Lai, Z., Zeng, Y., Li, J., Zhang, D., & Liu, X. (2021) · Nanoscale · doi:10.1039/d1nr00836f · Cited by 23
Monoclonal antibodies in cervical malignancy-related HPV
Aghbash, P. S., Hemmat, N., Fathi, H., & Baghi, H. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.904790 · Cited by 24
Intracellular antigens as targets for antibody based immunotherapy of malignant diseases
Wang, Y., Wang, X., Ferrone, C. R., Schwab, J. H., & Ferrone, S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.019 · Cited by 24
Self-citation
Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas
Schmitt, C., Marie‐Cardine, A., & Bensussan, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01010 · Cited by 25
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule
Kelton, C., Wesolowski, J. S., Soloviev, M., Schweickhardt, R. L., Fischer, D., Kurosawa, E., McKenna, S. D., & Gross, A. W. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.005 · Cited by 23
PD‐1 targeting in cancer immunotherapy
Ferris, R. L. (2012) · Cancer · doi:10.1002/cncr.27832 · Cited by 22
Self-citation
Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy
Machiels, J., & Schmitz, S. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328344f581 · Cited by 22
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
Gehlert, C. L., Rahmati, P., Boje, A. S., Winterberg, D., Krohn, S., Theocharis, T., Cappuzzello, E., Lux, A., Nimmerjahn, F., Ludwig, R. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957874 · Cited by 22
Biologically Targeted Therapeutics in Pediatric Brain Tumors
Rao, A. A. N., Scafidi, J., Wells, E. M., & Packer, R. J. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.02.005 · Cited by 22
How do I work up pretransfusion samples containing anti‐CD38?
Anani, W. Q., Duffer, K., Kaufman, R. M., & Denomme, G. A. (2017) · Transfusion · doi:10.1111/trf.14144 · Cited by 22
A novel leptin receptor antagonist uncouples leptin’s metabolic and immune functions
Zabeau, L., Wauman, J., Dam, J., Lint, S. V., Burg, E., Geest, J. D., Rogge, E., Silva, A. J., Jockers, R., & Tavernier, J. H. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03004-9 · Cited by 22
Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder
Kim, D., Kim, J., Kim, J.-S., Kim, S., & Kim, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051265 · Cited by 22
Immunotherapy as a Potential Treatment for Chordoma: a Review
Patel, S. S., & Schwab, J. H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0543-8 · Cited by 22
Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects
Khadela, A. D., Shah, Y. B., Mistry, P. S., Bodiwala, K. B., & Avinash, C. B. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221150559 · Cited by 21
Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer
Vyas, M., Koehl, U., Hallek, M. J., & von Strandmann, E. P. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.10.006 · Cited by 20
Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance
Guigay, J., Even, C., Mayache-Badis, L., Debbah, M., Saâda-Bouzid, E., Tao, Y., Deschamps, F., Janot, F., Lezghed, N., & Michel, C. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.03.009 · Cited by 20
MRI of Prostate Stem Cell Antigen Expression in Prostate Tumors
Ren, J., Zhang, Z., Wang, F., Yang, Y., Liu, Y., Wei, G., Yang, A., Zhang, R., Huan, Y., Cui, Y., et al. (2012) · Nanomedicine · doi:10.2217/nnm.11.147 · Cited by 20
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy
Denkert, C., Darb‐Esfahani, S., Loibl, S., Anagnostopoulos, I., & Jöhrens, K. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0261-0 · Cited by 20
Peptide vaccines in early breast cancer
Criscitiello, C., Viale, G., & Curigliano, G. (2019) · The Breast · doi:10.1016/j.breast.2019.02.003 · Cited by 20
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells
Zhou, T., Hou, X., Yan, J., Lin, L., Xie, Y., Bai, W., Jiang, W., Zou, Y., Li, X., Liu, Z., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332371 · Cited by 20
Selective Role of Mevalonate Pathway in Regulating Perforin but Not FasL and TNFalpha Release in Human Natural Killer Cells
Poggi, A. D., Boero, S., Musso, A., & Zocchi, M. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062932 · Cited by 19
Can Immunity to Breast Cancer Eliminate Residual Micrometastases?
Disis, M. L., & Stanton, S. E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0734 · Cited by 19
VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer
Xie, W., Liu, F., Wang, Y., Ren, X., Wang, T., Chen, Z., Tang, M., Sun, F., Li, Z., Wang, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7501 · Cited by 20
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Sacchetti, B., Botticelli, A., Pierelli, L., Nuti, M., & Alimandi, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081903 · Cited by 19
The Study on Newly Developed McAb NJ001 Specific to Non-Small Cell Lung Cancer and Its Biological Characteristics
Pan, S., Wang, F., Huang, P., Xu, T., Zhang, L., Xu, J., Li, Q., Xia, W., Sun, R., Huang, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033009 · Cited by 18
Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity
Trivedi, S., Jie, H.-B., & Ferris, R. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.003 · Cited by 18
Self-citation
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Olin, M. R., Pluhar, G. E., Andersen, B. M., Shaver, R. L., Waldron, N. N., & Moertel, C. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014011577 · Cited by 18
Advances in immunotherapy in multiple myeloma
Boussi, L. S., & Niesvizky, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000407 · Cited by 18
Gene status of head and neck squamous cell carcinoma cell lines and cetuximab‐mediated biological activities
Kondo, N., Tsukuda, M., Taguchi, T., Nakazaki, K., Sakakibara, A., Takahashi, H., Toth, G., & Nishimura, G. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01999.x · Cited by 17
Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells
Hartmann, S., Seher, A., Brands, R. C., Linz, C., Lessner, G., Böhm, H., Kübler, A. C., & Müller-Richter, U. D. A. (2014) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2014.03.018 · Cited by 17
CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
Jeon, S. H., Kang, M., Jeon, M., Chung, Y., Kim, A. R., Lee, Y. J., Kim, E.-S., Nam, H., Park, J., Lee, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1843 · Cited by 17
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity
Cui, Y., Yuan, T., Wang, Y., Zheng, D., Qin, L., Li, S., Jiang, Z., Lin, S., Guo, W., Wang, Z., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112797 · Cited by 17
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
Fiedler, W., Stoeger, H., Perotti, A., Gastl, G. A., Weidmann, J., Dietrich, B., Baumeister, H., Danielczyk, A., Goletz, S., Salzberg, M. O., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000381 · Cited by 17
Immunomodulatory Properties of Anticancer Monoclonal Antibodies: Is the ‘Magic Bullet‘ Still a Reliable Paradigm?
Correale, P., Cusi, M. G., & Tagliaferri, P. (2010) · Immunotherapy · doi:10.2217/imt.10.92 · Cited by 17
Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions
Miller, M. L., & Finn, O. J. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.07.026 · Cited by 16
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia
Pucciarelli, D., Lengger, N., Takáčová, M., Csáderová, L., Bartošová, M., Breiteneder, H., Pastoreková, S., & Häfner, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3010 · Cited by 16
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies
Leaf, R. K., Cho, H. J., & Avigan, D. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0283-0 · Cited by 18
MRl of Prostate Cancer Antigen Expression for Diagnosis and lmmunotherapy
Ren, J., Wang, F., Wei, G., Yang, Y., Liu, Y., Wei, M., Huan, Y., Larson, A. C., & Zhang, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038350 · Cited by 16
Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors
Patel, S. S., Nota, S. P. F. T., Sabbatino, F., Nielsen, G. P., Deshpande, V., Wang, X., Ferrone, S., & Schwab, J. H. (2020) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000001587 · Cited by 16
Self-citation
A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature
Russo, N., Wang, X., Liu, M., Banerjee, R., Goto, M., Scanlon, C. S., Metwally, T., Inglehart, R. C., Tsodikov, A., Duffy, S. A., et al. (2012) · Oncogene · doi:10.1038/onc.2012.532 · Cited by 15
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Hoesli, R. C., & Moyer, J. S. (2016) · Current Oral Health Reports · doi:10.1007/s40496-016-0082-2 · Cited by 15
AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor
Fazekas, J., Singer, J., Ilieva, K. M., Matz, M., Herrmann, I., Spillner, E., Karagiannis, S. N., & Jensen‐Jarolim, E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.04.021 · Cited by 15
Diverse Neoantigens and the Development of Cancer Therapies
Srivastava, R. M., Purohit, T. A., & Chan, T. A.-T. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.001 · Cited by 15
Clinical deployment of antibodies for treatment of melanoma
Curti, B. D., & Urba, W. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.025 · Cited by 14
The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody
Xu, M. M., Du, X., Liu, M., Li, S., Li, X., Fu, Y., & Wang, S. (2012) · Protein & Cell · doi:10.1007/s13238-012-2044-3 · Cited by 14
Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry
Helguera, G. F., Rodríguez, J. A., Lurı́a-Pérez, R., Henery, S., Catterton, P., Bregni, C., George, T. C., Martı́nez-Maza, O., & Penichet, M. L. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.03.003 · Cited by 14
Hidden Immunotherapy Targets Challenge Dogma
Ferrone, S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002821 · Cited by 14
Self-citation
Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
Che, Y., Zhang, Y., Wang, D., Liu, H., Shen, D., & Luo, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s212610 · Cited by 14
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
Stagg, J., André, F., & Loi, S. (2012) · Breast Care · doi:10.1159/000342166 · Cited by 14

Authors: Ferris, R. L., Jaffee, E. M., & Ferrone, S.
Affiliations: Johns Hopkins University (US)
ORCID: Ferris, Robert L.
Jaffee, Elizabeth M.
Ferrone, Soldano
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-10-01
Volume: 28
Issue: 28
Pages: 4390-4399
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.27.6360
PMC: PMC2954137
OpenAlex: W2112887207
Cited by: 320
References: 122
Citations by year: 2026: 6 · 2025: 12 · 2024: 7 · 2023: 28 · 2022: 11 · 2021: 13 · 2020: 17 · 2019: 19 · 2018: 13 · 2017: 30 · 2016: 26 · 2015: 33 · 2014: 18 · 2013: 28 · 2012: 34
FWCI: 3.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
American Society of Clinical Oncology
National Cancer Institute (P50CA097190)
National Institute of Dental and Craniofacial Research (R01DE019727)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: antibody-dependent cellular cytotoxicity, Fc gamma receptor polymorphisms, tumor immune evasion, cell-mediated immunity, rituximab, trastuzumab, cetuximab, signaling pathway inhibition
MeSH terms: Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Humans, Immunity, Cellular, Immunotherapy, Neoplasms, Receptors, Fc, Signal Transduction, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks